Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. (Q54626874)

1 June 2018

title

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. (English)

1 reference

1 June 2018

1 reference

dasatinib monohydrate

1 reference

1 reference

1 reference

C Lu-Emerson

1

1 reference

1 June 2018

A D Norden

2

1 reference

1 June 2018

J Drappatz

3

1 reference

1 June 2018

E C Quant

4

1 reference

1 June 2018

R Beroukhim

5

1 reference

1 June 2018

A S Ciampa

6

1 reference

1 June 2018

L M Doherty

7

1 reference

1 June 2018

D C Lafrankie

8

1 reference

1 June 2018

S Ruland

9

1 reference

1 June 2018

P Y Wen

10

1 reference

1 June 2018

publication date

14 December 2010

1 reference

1 June 2018

Journal of Neuro-Oncology

published in

1 reference

1 June 2018

volume

104

1 reference

1 June 2018

issue

1

1 reference

1 June 2018

page(s)

287-291

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s11060-010-0489-x

exact match

0 references

cites work

Malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Angiogenic inhibitors: a new therapeutic strategy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

What brings pericytes to tumor vessels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Cellular abnormalities of blood vessels as targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Time course of imaging changes of GBM during extended bevacizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Inhibition of angiogenesis and invasion in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Therapeutic strategies for inhibiting invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Mammalian ABC transporters in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0489-X

In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

21 January 2018

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions.

1 reference

12 December 2020

Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989

1 reference

12 December 2020

Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

1 reference

12 December 2020

Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.

1 reference

12 December 2020

10.1007/S11060-010-0489-X

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018